FDA Green-Lights Phase III Trial for Drug-Eluting Microspheres in Liver Cancer

OBTN
Published: Wednesday, Mar 09, 2011
The FDA has given Merit Medical Systems the green light for a phase III clinical trial investigating QuadraSphere Microspheres in patients with primary liver cancer. The drug-eluting microspheres release doxorubicin to the tumor and are approved for peripheral arteriovenous malformations and to embolize hypervascular tumors. The phase III study will take place in the United States and abroad, enrolling only those patients whose liver disease is localized and unresectable.


View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Community Practice Connections™: New Frontiers in Immuno-Oncology for Microsatellite Instability-High CancersAug 29, 20182.0
Community Practice Connections™: 1st Annual School of Nursing Oncology™Oct 31, 20181.5
Publication Bottom Border
Border Publication
x